MedTrace Logo

Innoventric Trillium™ Stent Graft Early Feasibility Study (EFS)

NCT06212193 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2025-03-07

No results posted yet for this study

Summary

Early Feasibility Study to evaluate the safety and performance of the Innoventric Trillium™ Stent Graft in the treatment of severe or greater tricuspid regurgitation (TR).

Conditions

  • Tricuspid Regurgitation
  • Tricuspid Regurgitation Functional

Interventions

DEVICE

Trillium™

Trillium™ Stent Graft for Cross-Caval Tricuspid Valve Replacement

Sponsors & Collaborators

  • Innoventric Inc.

    collaborator UNKNOWN

  • Innoventric LTD

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-05
Primary Completion
2025-08-31
Completion
2030-08-31
FDA Device
Yes

Countries

  • United States
  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06212193 on ClinicalTrials.gov